Cover Image
市場調查報告書

AuraSense Therapeutics, LLC:產品平台分析

AuraSense Therapeutics, LLC - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 341511
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
AuraSense Therapeutics, LLC:產品平台分析 AuraSense Therapeutics, LLC - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 27 Pages
簡介

AuraSense Therapeutics, LLC 是從事基於3次元球狀核酸 (SNA) 結構之免疫調節性及遺傳基因抑製藥物之開發及商品化的生物製藥公司。該公司的開發平台以球狀核酸為基礎,正在擴大到乾癬,膀胱癌,纖維症,糖尿病性潰瘍,發炎等的治療藥的開發。

本報告提供AuraSense Therapeutics, LLC 的治療藥開發平台的現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥被評估及休止的計劃相關資訊等

AuraSense Therapeutics, LLC的基本資料

  • AuraSense Therapeutics, LLC概要
  • 主要資訊
  • 企業資料

AuraSense Therapeutics, LLC:R&D概要

  • 主要的治療範圍

AuraSense Therapeutics, LLC:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

AuraSense Therapeutics, LLC:開發中產品概況

  • 初期階段的開發中產品
    • IND/CTA 所申請的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

AuraSense Therapeutics, LLC:藥物簡介

  • AST-005
  • AST-006
  • AST-008
  • Oligonucleotide to Agonize SRB1 for Atherosclerosis and Lymphoma
  • Oligonucleotides for Non-Alcoholic Steatohepatitis
  • Antisense Oligonucleotide to Inhibit IL-17 for Rheumatoid Arthritis

AuraSense Therapeutics, LLC:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AuraSense Therapeutics, LLC:暫停中的計劃

AuraSense Therapeutics, LLC:總公司和子公司的所在地

附錄

圖表

目錄
Product Code: GMDHC07536CDB

Summary

Global Markets Direct's, 'AuraSense Therapeutics, LLC - Product Pipeline Review - 2015', provides an overview of the AuraSense Therapeutics, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AuraSense Therapeutics, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of AuraSense Therapeutics, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AuraSense Therapeutics, LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AuraSense Therapeutics, LLC's pipeline products

Reasons to buy

  • Evaluate AuraSense Therapeutics, LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AuraSense Therapeutics, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AuraSense Therapeutics, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AuraSense Therapeutics, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AuraSense Therapeutics, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AuraSense Therapeutics, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AuraSense Therapeutics, LLC Snapshot
    • AuraSense Therapeutics, LLC Overview
    • Key Information
    • Key Facts
  • AuraSense Therapeutics, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • AuraSense Therapeutics, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AuraSense Therapeutics, LLC - Pipeline Products Glance
    • AuraSense Therapeutics, LLC - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AuraSense Therapeutics, LLC - Drug Profiles
    • AST-005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AST-006
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AST-008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Agonize SRB1 for Atherosclerosis and Lymphoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotides for Non-Alcoholic Steatohepatitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit IL-17 for Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AuraSense Therapeutics, LLC - Pipeline Analysis
  • AuraSense Therapeutics, LLC - Pipeline Products by Target
  • AuraSense Therapeutics, LLC - Pipeline Products by Route of Administration
  • AuraSense Therapeutics, LLC - Pipeline Products by Molecule Type
  • AuraSense Therapeutics, LLC - Pipeline Products by Mechanism of Action
  • AuraSense Therapeutics, LLC - Dormant Projects
  • AuraSense Therapeutics, LLC - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AuraSense Therapeutics, LLC, Key Information
  • AuraSense Therapeutics, LLC, Key Facts
  • AuraSense Therapeutics, LLC - Pipeline by Indication, 2015
  • AuraSense Therapeutics, LLC - Pipeline by Stage of Development, 2015
  • AuraSense Therapeutics, LLC - Monotherapy Products in Pipeline, 2015
  • AuraSense Therapeutics, LLC - IND/CTA Filed, 2015
  • AuraSense Therapeutics, LLC - Preclinical, 2015
  • AuraSense Therapeutics, LLC - Discovery, 2015
  • AuraSense Therapeutics, LLC - Pipeline by Target, 2015
  • AuraSense Therapeutics, LLC - Pipeline by Route of Administration, 2015
  • AuraSense Therapeutics, LLC - Pipeline by Molecule Type, 2015
  • AuraSense Therapeutics, LLC - Pipeline Products by Mechanism of Action, 2015
  • AuraSense Therapeutics, LLC - Dormant Developmental Projects,2015

List of Figures

  • AuraSense Therapeutics, LLC - Pipeline by Top 10 Indication, 2015
  • AuraSense Therapeutics, LLC - Pipeline by Stage of Development, 2015
  • AuraSense Therapeutics, LLC - Monotherapy Products in Pipeline, 2015
  • AuraSense Therapeutics, LLC - Pipeline by Top 10 Target, 2015
  • AuraSense Therapeutics, LLC - Pipeline by Top 10 Route of Administration, 2015
  • AuraSense Therapeutics, LLC - Pipeline by Top 10 Molecule Type, 2015
  • AuraSense Therapeutics, LLC - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top